Biologics development company AgeX Therapeutics added Michael May, PhD, to its board of directors, returning it to full strength.
Dr. May replaced an independent board member who recently left the board. He is the president and CEO of Canada's Centre for Commercialization of Regenerative Medicine and is heavily involved in the biologics space. He helped the Centre raise more than $100 million, which supported spinoff companies and helped develop academic partnerships.
AgeX Therapeutics board chairman Greg Bailey, MD, lauded the hiring, referring to Dr. May as a "globally-recognized leader in regenerative medicine."